Attached files
| file | filename |
|---|---|
| EX-4.1 - FORM OF ULURU WARRANT - ULURU Inc. | ex_4-1.htm |
| EX-5.1 - OPINION OF PARR BROWN GEE & LOVELESS - ULURU Inc. | ex_5-1.htm |
| EX-1.1 - ENGAGEMENT LETTER, DATED NOVEMBER 9, 2009 - ULURU Inc. | ex_1-1.htm |
| EX-10.1 - SECURITIES PURCHASE AGREEMENT, DATED NOVEMBER 11, 2009 - ULURU Inc. | ex_10-1.htm |
| 8-K - FORM 8K NOVEMBER 12, 2009 - ULURU Inc. | form8k_111209.htm |
EXHIBIT
99.1
ULURU
NEWS
Contact:
Company
Renaat
E. Van den
Hooff
President
&
CEO
Terry
K.
Wallberg
Vice
President &
CFO
(214)
905-5145
ULURU INC. TO RAISE $1.5
MILLION IN REGISTERED DIRECT OFFERING
Addison, Texas, November 12, 2009;
ULURU Inc. (NYSE Alternext: ULU), a specialty pharmaceutical company
focused on the development of a portfolio of wound management and oral care
products, today announced it has entered into definitive agreements to sell
10,714,467 shares of its common stock at a price per share of $0.14 pursuant to
a registered direct offering to institutional investors, resulting in gross
proceeds of approximately $1.5 million.
Investors
will also receive warrants to purchase up to 5,357,233 shares of ULURU Inc.’s
common stock. The warrants have an exercise price of $0.19 per share and are
exercisable at any time on or after 6 months and prior to 5 year anniversary of
such initial issuance date.
The
closing of the offering is expected to take place subject to the satisfaction of
customary closing conditions. ULURU Inc. plans to use the net proceeds from the
offering for research and development and general corporate
purposes.
Rodman
& Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.
(NasdaqGM: RODM), acted as the exclusive placement agent for this
transaction.
About
ULURU Inc.:
ULURU Inc. is a specialty
pharmaceutical company focused on the development of a portfolio of wound
management and oral care products to provide patients and consumers improved
clinical outcomes through controlled delivery utilizing its innovative Nanoflex™
Aggregate technology and OraDisc™ transmucosal delivery system. For further
information about ULURU Inc., please visit our website at www.ULURUinc.com. For
further information about Altrazeal™, please visit www.Altrazeal.com.
This
press release contains certain statements that are forward-looking within the
meaning of Section 27a of the Securities Act of 1933, as amended, including but
not limited to statements made relating to the anticipated closing of the
transaction and the Company’s products. These statements are subject to numerous
risks and uncertainties, including but not limited to ULURU’s lack of
profitability, the need for additional capital to operate its business, and to
risk factors detailed in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2008, and other reports filed by us with the Securities and
Exchange Commission.